There is intense interest by pharmaceutical companies in the development of potent and selective BETi as therapeutics for a myriad of diseases, and current trials seek to attenuate BET activity in settings as diverse as oncology, diabetes, and atherosclerosis; indeed, several studies have already combined current standard of care with BETi [49]. This evidence concerns the gene DNER and diabetes mellitus.